相关临床试验
2
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1994
暂无试验阶段数据
进行中（未招募）
2
100.0%
暂无批准数据
- The University of the Sunshine Coast has developed and received regulatory approval for the world's first single-dose vaccine to protect koalas from chlamydia, a disease that causes up to half of koala deaths in wild populations. - Clinical trials demonstrated the vaccine reduces mortality from chlamydia by at least 65% and decreases the likelihood of symptomatic disease during breeding age in wild koala populations. - The vaccine targets Chlamydia pecorum's major outer membrane protein and offers three levels of protection: reducing infection, preventing disease progression, and potentially reversing existing symptoms. - With some wild koala colonies experiencing infection rates as high as 70%, this breakthrough represents a critical intervention for conserving Australia's endangered marsupial populations.
- A pilot study at the University of the Sunshine Coast found that low doses of oral ketamine significantly reduced PTSD symptoms in participants. - 73% of participants reported a reduction of more than half in their PTSD symptoms one week after completing the six-week oral ketamine treatment. - Oral ketamine offers a potentially more accessible and affordable alternative to intravenous ketamine for PTSD treatment, with fewer reported side effects. - The study also noted improvements in depression, stress, suicidal ideation, sleep quality, and overall wellbeing among participants.
